Piper Sandler Maintains Neutral on Hims & Hers Health, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Korinne Wolfmeyer maintains a Neutral rating on Hims & Hers Health (HIMS) and raises the price target from $11 to $13.

May 07, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Hims & Hers Health but raises the price target from $11 to $13.
The increase in the price target by Piper Sandler suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the maintenance of a Neutral rating indicates that the analyst sees limited upside beyond the new target, tempering expectations for a significant rally.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100